Introduction: Recent research shows that advance care planning (ACP) for patients with Chronic Obstructive Pulmonary Disease (COPD) is uncommon and poorly done. Aim of the present study is to explore whether and to what extent structured ACP by a trained nurse, in collaboration with the chest physician, can improve outcomes in Dutch patients with COPD and their family.
The study will include patients with severe to very severe COPD and their families.
Strengths and limitations of this study
The present study is a large, adequately powered, multicentre randomized controlled trial to investigate the effects of ACP in patients with (very) severe COPD.
The results from this study will help to implement ACP in regular clinical care and will provide recommendations for guidelines on palliative care in COPD.
Quality of end-of-life care and dying will be assessed subjectively and retrospectively. Therefore we will use well validated instruments to overcome this limitation.
The current intervention consists of one single intervention, whereas ACP is an on-going process of communication. However, with this intervention we aimed to facilitate this continuous process between patients, families and physicians. Previous studies have shown that ACP increases the occurrence of discussions about ACP 3 4 , improves concordance between patient's preferences and end-of-life care received [5] [6] [7] , and improves quality of care at the end-of-life 8 in different adult populations. Despite the fact that chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide 9 and unexpected deaths occur frequently 10 , ACP studies are rarely focused on patients with COPD. A prospective crosssectional study showed that outpatients with COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage III or IV are able to discuss preferences about life-sustaining treatments and are willing to discuss end-of-life care preferences. However, discussions about end-of-life care are rare and patients rated the quality of patient-physician communication about end-of-life care as poor 11 .
The most common endorsed barriers for end-of-life care communication reported by physicians are lack of time, anxiety to take away patient's hope, and the assumption that the patient is not ready to talk about end-of-life care 12 .
Although patients often prefer doctors to discuss ACP, they also accept other healthcare professionals as sources of ACP information. Nurses, for example, have specific skills that may facilitate communication about end-of-life care. They can provide prognostic information and support patients' hopes by understanding individual aspects of hope, focusing on patient's quality of life, and building trust with patients 13 .
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Hypothesis to be examined in the study
We hypothesize that structured ACP by a trained nurse, in collaboration with the patient's physician, can improve quality of end-of-life care communication, as well as quality of end-of-life care and quality of dying for patients with COPD. In addition, we hypothesize that structured ACP won't result in increased symptoms of anxiety or depression.
METHODS AND ANALYSIS
Study design
A multicentre, cluster-randomized controlled trial has been designed. Patients with COPD who were recently discharged after an exacerbation will be recruited in an academic hospital and two general hospitals in the Netherlands. Patients in the intervention group will receive an ACP intervention within four weeks after discharge. The control group will receive usual care. The intervention and control group will be assessed at baseline and six and 12 months after enrolment ( Figure 1 ).
Eligibility criteria
Eligible patients are those who satisfy all of the following criteria:
1. A diagnosis of severe to very severe COPD (GOLD grade III or IV) 14 .
2. Discharged after hospital admission for a COPD exacerbation.
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Patients will be excluded if they are unable to complete the questionnaires because of cognitive impairment or if they are unable to speak or understand Dutch.
Intervention
Respiratory nurse specialists will receive a two-day training to be able to perform the intervention. The training will consist of theory about the importance and benefits of ACP for patients with COPD and their loved ones. End-of-life care communication skills and the structured ACP session during the study will be taught and practiced. Participants will be asked to perform ACP with a standardized patient. Investigators will use a checklist to confirm adherence to the standardized protocol for ACP and provide certification if participants have achieve competency.
Certified respiratory nurse specialists will provide the structured ACP session in the patient's home environment in the presence of the patient and his or her loved one(s) within 4 weeks after discharge. The session will be prepared with the chest physician in advance. The structured ACP session will pay attention to several elements ( Table 1) . The content will be adapted to the patient's needs. The duration will be about 1.5 hours. Respiratory nurse specialists will be supervised by the research project team regularly to guarantee the quality of the structured ACP session.
As part of the structured ACP session, the respiratory nurse specialists will complete, together with the patient, a feedback form showing patient's: general goals of care; preferences for life-sustaining treatments (cardiopulmonary resuscitation, non-invasive positive pressure ventilation, and mechanical ventilation); and questions and concerns regarding end-of-life care. This feedback form will be provided to the patient, the chest physician and the general practitioner. Finally, patients will receive a brochure about palliative care for patients with COPD. This brochure is based on the Dutch guideline "palliative care for patients with COPD" and was developed for patients and their loved ones by the Lung Foundation Netherlands. 
Outcomes
The following variables will be recorded during home visits at baseline and after six months in patients in the intervention and usual care group: demographics (including age, sex, educational level, religion); smoking history; medical history; current medication; post-bronchodilator Forced Expiratory Volume in the first second (FEV 1 ); use of long-term oxygen therapy; and use of noninvasive positive pressure ventilation.
Primary outcomes
Primary outcomes for all patients are:
-Quality of communication about end-of-life care (Quality of Communication (QOC)) 15 ;
-Symptoms of anxiety and depression (Hospital Anxiety and Depression Scale (HADS)) 16 ;
For patients who died during the study period, primary outcomes are: -Quality of end-of-life care (Toolkit After-Death Bereaved Family Member Interview) 17 ;
-Quality of death and dying (Quality of Death and Dying (QODD)) 18 .
Secondary outcomes
Secondary outcomes are: -Concordance between patient's preferences for end-of-life care (patient's preferences for cardiopulmonary resuscitation (CPR) and mechanical ventilation; End-of-life Preferences Interview (ELPI) 19 and received end-of-life care (life-sustaining treatment before dying;
Toolkit After-Death Bereaved Family Member Interview) 17 ;
-Psychological distress in bereaved family members of deceased patients with COPD (HADS 16 ;
Inventory of Complicated Grief (ICG) 20 ).
Patients in the intervention and usual care group will receive a phone call 12 months after enrolment to assess survival state. If the patient cannot be reached, the participating family 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y members will be contacted. If the patient deceased during the study period, a bereavement interview will be conducted with the participating family members. The following outcomes will be assessed: QODD 18 ; Toolkit After-Death Bereaved Family Member Interview 17 ;ICG 20 ; and HADS 16 .
Questionnaires that were not available in Dutch (QOC, ELPI, and Toolkit After-Death Bereaved Family Member Interview) have been translated into Dutch using a forward-backward translation procedure.
Sample size
A sample size calculation with a level of significance of 5% and a power of 90% has shown that 53 patients per group are needed in order to detect a difference of 1.0 point change in QOC endof-life care domain score (standard deviation (SD) estimated as 2.53 points) 15 between the intervention and control group. A sample size calculation with a level of significance of 5% and power of 90% has shown that 32 deceased patients per group are needed in order to detect a difference of 10 points change in QODD scores between the intervention and control group. Since we expect a mortality rate within one year of about 23% and a dropout rate of about 10% because of other reasons, we will include 150 patients per group.
Recruitment and randomization
Patients will be informed about the study during their hospital admission for a COPD exacerbation. After discharge, the potential subject will receive a phone call. If the patient wants to participate an appointment for a first home visit will be made. Informed consent will be obtained at the start of this visit. Each subject will be assigned a study identification number. A list with identification codes linking the subject's names to subject's identification numbers will be stored in a limited access space.
Chest physicians of participating hospitals will be randomized into an intervention or usual care group using sealed opaque envelopes. We will cluster for chest physician to prevent cross-
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Data management and statistical analysis
The data will be screened for outliers and missing values. These values will be excluded by list wise deletion. Missing data will be minimized because patients will be visited at home for completing the questionnaires and the researcher will check if all the questions have been answered. The study variables will be tested for normality. Demographic variables (such as age, sex, educational level, religion, and smoking history) will be compared between patients in the intervention group and control group, using independent-samples T-tests or Mann-Whitney U-tests, as appropriate, for continuous variables and Chi-square tests for categorical variables.
Differences in primary outcome measures between the intervention and the usual care group will be compared using independent-samples T-tests or Mann-Whitney U-tests, as appropriate. The Wilcoxon Signed Rank Test will be used to compare changes in primary outcome measures within the intervention and usual care group. Multivariate regression models will be developed to compare changes in primary and secondary outcome measures between the intervention and control group while clustering by physician and controlling for possible confounders. Finally, concordance between the patient's preferences for end-of-life care and the end-of-life care received will be calculated using Intraclass Correlation Coefficients (ICC) for continuous variables and Cohen's kappa for categorical variables.
All statistical analyses will be performed using statistics software (SPSS version 21.0 for Windows, Chicago, IL, USA) and STATA 11.1 (StataCorp LP, College Station, TX, USA) for clustered regression analysis. A priori, a two-tailed p-value of <0.05 was considered as significant.
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Ethics and dissemination
The protocol of the present study has been approved by the Medical Ethical Committee of the Catharina Hospital Eindhoven, the Netherlands (NL42437.060.12) and is registered in the Dutch Trial Register (NTR3940). The study will be monitored according to the guidelines of the Dutch Federation of University Medical Centres (NFU) and will be conducted in accordance with the Medical Research Involving Human Subjects Act (WMO). The results will be submitted for publication in peer-reviewed journals and will be presented at (inter)national conferences. Participants will be informed about the results of the study. The results of this project provide direction for further development of palliative care for patients with COPD.
DISCUSSION
The present study has been designed to examine whether and to what extent structured ACP by a trained nurse, in collaboration with the chest physician, can improve outcomes for patients with advanced COPD and their family. The study has several strengths and limitations which will be described below.
Strengths
The current project is designed to improve ACP by overcoming the previously reported physician- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 11 22 . These discussions about end-of-life care are particularly important for patients with COPD, because they follow a disease trajectory characterized by a gradual decline in health status and punctuated by exacerbations 23 . Although survival in patients with COPD is hard to predict 24 , research has shown that exacerbations are associated with an increased risk of dying 25 . Patients who survived a hospitalization for an exacerbation often experience an increase in the intensity of dyspnea and had a poor quality of life 26 27 . Therefore, clinicians see exacerbations as a clinical event that defines an important transition in the course of the disease and is therefore a moment to initiate ACP 28 . In addition, patients who were hospitalized for an exacerbation describe the hospital admission itself as chaotic, but are willing to discuss their preferences for end-of-life care after discharge 29 . Consequently, an approach may be to discuss ACP after discharge.
The present study also has some methodological strengths. First, the present study is a randomized controlled trial. This study design in general has good validity and causal conclusions can be drawn 30 . Second, patients will be recruited in one academic and two general hospitals in the Netherlands to guarantee internal and external validity. Finally, we will perform cluster-analysis to prevent cross-contamination between the intervention and usual care group and allocation is concealed using sealed opaque envelops in order to prevent systematic biases.
Limitations
The present study has the following limitations:
First, it may be possible that eligible patients and family members who refuse participation in this study are less willing to discuss issues concerning end-of-life care than participating patients and family members. Demographics will be collected from eligible patients and family members who refuse participation in the study for comparison with participating patients and family members.
However, since these patients may also refuse an ACP intervention in clinical practice, this may mitigate the importance of this limitation. Second, drop-out is to be expected and unavoidable in a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 longitudinal study including patients with severe disease. We expect about 23% of the patients to die during the study period 31 . In addition, we expect about 10% to withdraw because of other reasons 22 .
Third, in the present study the perception of the patient of communication about end-of-life care will be assessed. The present project does not provide objective measures for quality of communication.
In addition, the present project assesses the family members' perception of quality of end-of-life care and quality of dying and does not provide objective measures for quality of end-of-life care and quality of dying. However, we believe that the perception from the patient and his or her family members is the most important construct with respect to end-of-life care. Moreover, validated instruments will be used to assess the patient perception from quality of communication about endof-life care 15 and the family members' perception of quality of end-of-life care and quality of death and dying 17 18 . Fourth, quality of end-of-life care and quality of dying will be assessed retrospectively.
We do not assess prospectively quality of end-of-life care in terminally ill patients. Prospectively identifying terminally ill patients with COPD is extremely difficult 10 . Moreover, we want to avoid extra burden for dying patients. However, retrospective assessments may be altered by grief or recall difficulties 32 . This should be taken into account in interpreting the results. Fifth, it may be possible that quality of communication about end-of-life care at baseline is different between the physicians in the intervention group and physicians in the usual care group. Therefore, data-analysis will correct for baseline QOC scores. Sixth, it may be possible that participants in the usual care group will be stimulated to discuss their life-sustaining treatment preferences or end-of-life care due to the assessment of their preferences during the study period. However, a prior study suggested that these questionnaires do not have a significant effect on discussions about end-of-life care 33 . Finally, the current intervention consists of a single session with a trained respiratory nurse specialist and providing a feedback form. We acknowledge that ACP should not be a single intervention, but should be an on-going process between patients, their loved ones and professional caregivers during the course of the disease. However, the aim of the intervention in the present study is to facilitate the on-going process of ACP between patients, families and physicians.
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Clinical consequences
The present study will examine the effects of structured ACP by a trained respiratory nurse.
When this relatively simple intervention is able to improve outcomes for patients regarding end-oflife care and their loved ones, the project can be followed by implementation of ACP in regular clinical care. In addition, the current project provides recommendations for guidelines on palliative care in COPD. Moreover, if the current intervention is able to improve outcomes for patients with COPD and their families, this program can possibly be implemented for other patients with advanced chronic life-limiting diseases, like congestive heart failure or idiopathic pulmonary fibrosis. Indeed, mortality rates are also high in these patient populations 34 35 .
Conclusion
To date, ACP for patients with severe to very severe COPD is uncommon and poorly done.
The present study aims to improve quality of end-of-life care communication, as well as quality of end-of-life care and quality of dying for patients with COPD using structured ACP by a trained nurse, in collaboration with the patient's chest physician. This study is necessary to develop an evidence based ACP program in the Netherlands. Here, the study protocol is described and a preliminary analysis of the possible strengths and weaknesses is outlined.
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Ethics approval
Ethics approval has been obtained from the Medical Ethical Committee of the Catharina Hospital Eindhoven, The Netherlands (NL42437.060.12).
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5c
Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities 14 5d
Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) n.a.
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20c
Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) 9
Methods: Monitoring
Data monitoring 21a
Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed 10 21b
Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial _____________ 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  Consent or assent  26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
26b
Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable _____________
Confidentiality 27
How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial _____________
Declaration of interests 28
Financial and other competing interests for principal investigators for the overall trial and each study site 14
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators _____________ Ancillary and posttrial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation _____________ Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions 10 31b
Authorship eligibility guidelines and any intended use of professional writers _____________ 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code _____________
Appendices
Informed consent materials 32
Model consent form and other related documentation given to participants and authorised surrogates _____________ Biological specimens 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable n.a.
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.
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